CHEBI:238698 - bevantolol

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name bevantolol
ChEBI ID CHEBI:238698
Definition A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A β1 adrenoceptor antagonist, it has been shown to be as effective as other β-blockers for the treatment of angina pectoris and hypertension.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Formula C20H27NO4
Net Charge 0
Average Mass 345.43270
Monoisotopic Mass 345.194
InChI InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
InChIKey HXLAFSUPPDYFEO-UHFFFAOYSA-N
SMILES COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
calcium channel blocker
One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
Application(s): beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
antihypertensive agent
Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing bevantolol (CHEBI:238698) has role β-adrenergic antagonist (CHEBI:35530)
bevantolol (CHEBI:238698) has role anti-arrhythmia drug (CHEBI:38070)
bevantolol (CHEBI:238698) has role antihypertensive agent (CHEBI:35674)
bevantolol (CHEBI:238698) has role calcium channel blocker (CHEBI:38215)
bevantolol (CHEBI:238698) is a propanolamine (CHEBI:35533)
Incoming bevantolol hydrochloride (CHEBI:31282) has part bevantolol (CHEBI:238698)
(R)-bevantolol (CHEBI:59184) is a bevantolol (CHEBI:238698)
(S)-bevantolol (CHEBI:59185) is a bevantolol (CHEBI:238698)
IUPAC Name
1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
INNs Sources
bevantolol ChemIDplus
bévantolol WHO MedNet
bevantolol WHO MedNet
bevantololum ChemIDplus
Synonyms Sources
(±)-bevantolol ChEBI
1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol ChemIDplus
1-(3,4-dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol ChemIDplus
1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol ChEBI
1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol ChEMBL
Manual Xrefs Databases
360 DrugCentral
BE790165 Patent
DB01295 DrugBank
US3857891 Patent
US4994618 Patent
View more database links
Registry Numbers Types Sources
2769444 Reaxys Registry Number Reaxys
2769444 Beilstein Registry Number Beilstein
59170-23-9 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
2871781 PubMed citation Europe PMC
2894292 PubMed citation Europe PMC
Last Modified
22 February 2017